 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || fidrisertib (IPN60130) / Ipsen
Enrollment closed, Trial completion date: FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov) - Sep 20, 2024
P2, N=113, Active, not recruiting, Sponsor: Clementia Pharmaceuticals Inc.
Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Mar 2029
- | fidrisertib (IPN60130) / Ipsen
Preclinical, Journal: An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. (Pubmed Central) - May 29, 2024
Delayed dosing revealed a short 2-day window after injury when BLU-782 treatment prevented HO in ALK2R206H mice, but dosing delays of 4 days or longer abrogated HO prevention. Together, these data suggest that BLU-782 may be a candidate for prevention of HO in FOP.
- fidrisertib (IPN60130) / Ipsen
Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva: Methodology of the Randomized, Double-Blind, Placebo-Controlled Phase II FALKON Trial (MTCC - Exhibit Halls DE) - Jan 10, 2024 - Abstract #ACMG2024ACMG_930;
P2
Together, these data suggest that BLU-782 may be a candidate for prevention of HO in FOP. Results from FALKON will allow evaluation of fidrisertib in FOP.
- | fidrisertib (IPN60130) / Ipsen
Trial completion date: FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov) - Jul 10, 2023
P2, N=98, Recruiting, Sponsor: Clementia Pharmaceuticals Inc.
Results from FALKON will allow evaluation of fidrisertib in FOP. Trial completion date: Aug 2025 --> Aug 2029
- || fidrisertib (IPN60130) / Ipsen
Trial primary completion date: FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov) - Feb 4, 2022
P2, N=90, Recruiting, Sponsor: Clementia Pharmaceuticals Inc.
Trial completion date: Aug 2025 --> Aug 2029 Trial primary completion date: Jul 2023 --> Aug 2025
- || fidrisertib (IPN60130) / Ipsen
Trial primary completion date: FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov) - Jan 25, 2022
P2, N=90, Recruiting, Sponsor: Clementia Pharmaceuticals Inc.
Trial primary completion date: Jul 2023 --> Aug 2025 Trial primary completion date: Aug 2025 --> Jul 2023
- ||| fidrisertib (IPN60130) / Ipsen
Enrollment open: FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov) - Dec 17, 2021
P2, N=90, Recruiting, Sponsor: Clementia Pharmaceuticals Inc.
Trial primary completion date: Aug 2025 --> Jul 2023 Not yet recruiting --> Recruiting
- |||| fidrisertib (IPN60130) / Ipsen
New P2 trial: FALKON: A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (clinicaltrials.gov) - Sep 8, 2021
P2, N=90, Not yet recruiting, Sponsor: Clementia Pharmaceuticals Inc.
- ||| fidrisertib (IPN60130) / Ipsen
Trial completion, Enrollment change, Trial primary completion date: Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults (clinicaltrials.gov) - Nov 15, 2019
P1, N=108, Completed, Sponsor: Blueprint Medicines Corporation
Not yet recruiting --> Recruiting Recruiting --> Completed | N=80 --> 108 | Trial primary completion date: Jun 2019 --> Sep 2019
- ||| fidrisertib (IPN60130) / Ipsen
New P1 trial: Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults (clinicaltrials.gov) - Feb 27, 2019
P1, N=80, Recruiting, Sponsor: Blueprint Medicines Corporation